For BRAF V600E mutant NSCLC, acquired resistance after dabrafenib monotherapy is caused by oncogenic KRAS mutations and subsequent sustained BRAF non-dependent MEK activation (156). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.